While cryptosporidiosis, infection by the protist parasite Cryptosporidium, is rare in the United States, it is a common ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

Shiny new Jade Biosciences has selected its CEO in Tom Frohlich, who co-founded Chinook Therapeutics and served as chief ...

Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

GenSight Biologics is weeks away from running out of money. Again. | GenSight Biologics is weeks away from running out of ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...